SCHEMBL196773

SCHEMBL196773

COC(=O)c1ccc(C2(C(=O)N=C(C)N(C)C)CCOCC2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 4/20 0.43
POLB P06746 3/20 0.43
CYP2C9 P11712 2/20 0.43
NPSR1 Q6W5P4 1/20 0.41
ALDH1A1 P00352 3/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
HPGD P15428 2/20 0.40
MAPT P10636 2/20 0.40
ALOX15 P16050 1/20 0.40
MGLL Q99685 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
LMNA P02545 1/20 0.37
TSHR P16473 1/20 0.37
CYP1A2 P05177 1/20 0.37
PKM P14618 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL198271 0.75 ALDH1A1 (0.52) CYP2C19POLBCYP2C9NPSR1ALDH1A1
SCHEMBL19331211 0.74 ALDH1A1 (0.50) CYP2C19POLBCYP2C9ALDH1A1NPC1
SCHEMBL25331702 0.72 ALDH1A1 (0.51) CYP2C19POLBCYP2C9ALDH1A1NPC1
SCHEMBL19343554 0.72 POLB (0.46) CYP2C19POLBCYP2C9NPSR1ALDH1A1
SCHEMBL6616887 0.72 CA1 (0.48) ALDH1A1NPC1RAB9AHPGDMAPT
SCHEMBL6616890 0.72 CA1 (0.48) ALDH1A1NPC1RAB9AHPGDMAPT
SCHEMBL23163550 0.70 POLB (0.58) CYP2C19POLBCYP2C9NPSR1ALDH1A1
SCHEMBL27078165 0.70 POLB (0.58) CYP2C19POLBCYP2C9NPSR1ALDH1A1
SCHEMBL2701049 0.69 ALDH1A1 (0.48) CYP2C19POLBCYP2C9NPSR1ALDH1A1
SCHEMBL19343552 0.69 ALDH1A1 (0.44) CYP2C19POLBCYP2C9ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198299-B2 Cycloalkylidene and heterocycloalkylidene inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-06-12 US disclosed
US-20120045412-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-02-23 US disclosed
US-8088771-B2 Cycloalkylidene and heterocycloalkylidene inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-01-03 US disclosed
US-20100022543-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120045412-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC2 CYP2C19 2879/4885POLB 718/4885CYP2C9 3368/4885
US-20100022543-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC2 CYP2C19 2879/4885POLB 718/4885CYP2C9 3368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.